Sector News

Pharma comments on Brexit withdrawal rejection

January 16, 2019
Life sciences

Pharmaceutical groups have weighed in on the UK parliament’s rejection of the Brexit withdrawal agreement.

Commenting on the decision made by UK parliament to vote down Prime Minister Theresa May’s Brexit withdrawal agreement, the European Federation of Pharmaceutical Industries and Associations (EFPIA) urged negotiators to agree on certain actions that it says need to be taken in order to protect patients.

“With the prospect of the UK leaving the EU in a disorderly manner on March 30, 2019, without a deal, there are very real, tangible and immediate threats to patient safety and public health in both the UK and across Europe.”

It also recommended the development of measures to recognise UK-based testing until it can be transferred to the EU.

In addition, the industry group called for continued UK participation in key data-sharing platforms that protect public health and drug safety in Europe, in addition to discussions between relevant authorities and the sector to formulate contingency plans such as creating fast track lanes or priority routes for drugs through ports and airports.

Also commenting on the deal’s demise, Mike Thompson, chief executive of the ABPI, said: “We reiterate that ‘no deal’ would prove to be extremely challenging. With time running out we hope Parliament will come together and quickly find a solution to the stalemate and reassure patients that medicines will not be disrupted come March 2019.”

The news comes shortly after the UK government warned that access at UK ports could be significantly reduced for up to six months if the country leaves the EU without an exit agreement. Previously, the UK’s Department of Health and Social Care asked drugmakers to stockpile at least six weeks’ worth of medicines to ensure that drug access was not interrupted for NHS patients in the case of a no-deal Brexit.

Gavin Davidson, Pharma Analyst at GlobalData, offered his view on how Brexit could impact the UK healthcare industry’s contribution to the UK economy:

“Throughout 2018, the global biopharma industry’s opinion of the UK as an attractive place to base research and manufacturing has steadily eroded and last night’s vote will have done nothing to improve this sentiment with the looming possibility of a ‘No Deal Brexit’.

‘‘In a series of quarterly surveys (Q1-Q3), GlobalData asked key respondents from the US, UK, and EU healthcare markets, whether or not they thought that the UK will remain an attractive place to do central business. In all markets, decreases in ‘yes’ answers were observed; however in the UK and EU markets, confidence has collapsed with abysmal rates of 17% and 19% respectively after Q3.”

“The UK has always been at the forefront of pharmaceutical and biotechnical investment and development. For this position to be maintained, companies based in the UK want certainty on the outcome of Brexit and with MPs now debating ‘what next’, the stakes couldn’t be higher with the healthcare industries’ £70 billion ($88.5 billion) per annum contribution to the UK economy at risk if the country ends up with a no deal Brexit, an outcome that the EU has now escalated its planning for.”

By Anna Smith

Source: Pharma Times

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach